Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms

Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms Angel J. Magaña, Kimberly Phan, Jesse Lopez, Maria S. Ramirez, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7390173/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Antisense interference with gene expression is usually achieved using nuclease-resistant oligonucleotide analogs that act by mRNA degradation, recruiting endogenous RNase H or RNase P, or steric hindrance of translation. Bridge nucleic acids (BNAs) are promising nucleotide analogs, and their chemical structure allows the development of new variants. Building on previous research, we evaluated gapmers composed of a short oligodeoxynucleotide flanked by BNA residues in a BNA 5 -DNA 8 -BNA 4 configuration, using available BNA variants: the original locked nucleic acid (LNA; 2′-O-4′-methylene locked nucleic acid), cET (2′-O,4′-ethyl bridge), cMOE (2′-O,4′-methoxyethyl bridge), and BNA NC (2′-O,4′-aminomethylene bridge). These gapmers were tested in vitro for their ability to direct cleavage of the aac(6')-Ib mRNA, which would restore susceptibility to clinically important aminoglycosides. The assays were carried out using gapmers that target a region of the mRNA previously identified as suitable for interaction with antisense oligomers. While all gapmers showed variable RNase H-mediated activity, only the LNA-containing gapmer (LDAA) elicited RNase P-dependent degradation, demonstrating ability to mimic both RNA and DNA. Coupled in vitro transcription–translation reactions using a cell lysate or a reconstituted system confirmed inhibition of expression and ruled out steric hindrance as mechanism of action. Gapmers with the LDAA structure can act as external guide sequences (EGSs), molecules that elicit RNAse P cleavage, and as antisense compounds that work via RNase H degradation. In contrast, gapmers targeting the ribosome binding site failed to recruit endogenous RNases but strongly inhibited expression by steric hindrance. Taken together, the results show that LNA-containing gapmers with the tested configuration can act through multiple mechanisms. A single molecule can elicit both RNase H- and RNase P-mediated degradation, and, when directed to other regions such as the ribosome binding site, inhibit expression through steric hindrance, supporting the potential for synergistic inhibition of gene expression when used in combination. Biological sciences/Biochemistry Biological sciences/Drug discovery Biological sciences/Molecular biology antisense bridge nucleic acid RNase P RNase H aminoglycoside antibiotic resistance Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Antisense technologies are a group of approaches designed to interfere with harmful biological processes by reducing the expression of target genes using complementary oligonucleotides or oligonucleotide analogs 1 – 7 . In the case of eukaryotic systems, these technologies can also be utilized to modify splicing of pre-mRNA and modify expression or correct defects 1 , 4 , 8 , 9 . Although these technologies face numerous challenges, such as stability, toxicity, delivery, and cellular penetration, many antisense drugs have been introduced in the market, and many others are in development 2 , 3 , 7 , 10 . However, most drugs approved or in advanced clinical trials do not target bacterial pathogens. Despite considerable past and ongoing efforts 11 – 15 , developing effective antisense pharmacological tools against bacterial infections remains an unmet challenge 3 . Interference with gene expression mediated by antisense compounds can mostly occur by steric hindrance, where the antisense impedes the binding or progression of the ribosome along the mRNA or through eliciting cleavage of the target mRNA 3 , 5 , 6 . Various strategies to induce steric hindrance or mRNA degradation have been explored. Two particularly intensive research areas focus on turning off prokaryotic genes by promoting the degradation of the target mRNA through recruiting endogenous RNases like RNase H or RNase P 2 , 3 , 10 . The former alternative takes advantage of the property of the endonuclease RNase H, an enzyme characterized by its ability to cleave RNA when it is in a duplex with DNA in a non-sequence-specific manner 16 . The latter utilizes the ribozyme RNase P, which, in conjunction with a protein cofactor, cleaves duplex RNA:RNA in a structure-specific but sequence-nonspecific manner 17 . In this case, the antisense molecule is known as "external guide sequence" (EGS), and the general approach is known as EGS technology 17 – 19 . Viable antisense drugs must resist nucleases that could degrade them before reaching their target. This property can be achieved by constructing oligomers totally or partially composed of nucleotide analogs 2 , 20 – 22 . However, the oligomers must retain their ability to bind the complementary sequence, and the endogenous enzyme must recognize the duplex as substrate. If RNase H is the intended cleavage agent, the analog must resemble DNA when interacting with the target. On the other hand, if the desired compound should behave as an EGS, i.e., cleavage occurs via RNase P digestion, the antisense bound to the target must resemble a duplex RNA:RNA with the appropriate structure. A way to improve the efficiency of antisense-mediated gene silencing could be to recruit both endogenous RNases to degrade the target mRNA. To test this possibility, we aimed to design oligonucleotide analogs capable of eliciting degradation of the target mRNA by both RNase H and RNase P. As a model, we used the aac(6ʹ)-Ib gene, which encodes the aminoglycoside 6'- N -acetyltransferase type Ib [AAC(6')-Ib]. This enzyme is responsible for the inactivation of amikacin in most amikacin-resistant Gram-negative bacteria 23 , 24 . Inhibition of expression of aac(6ʹ)-Ib would enable the use of amikacin and other aminoglycosides to treat severe multidrug-resistant infections 25 . Our previous research showed that hybrid oligomers containing bridge nucleic acid (BNA) and deoxyribonucleotide residues in a gapmer configuration were promising analogs for recruiting RNase P to cleave target mRNA molecules and turn off expression of bacterial genes 22 , 26 , 27 . Since the early development of the first bridge nucleic acid, known as locked nucleic acid (LNA), characterized by a methylene group linking the 2′-oxygen and the 4′-carbon of the ribose residue (2′- O ,4′-methylene-β-d-ribofuranosyl nucleotides), other BNA derivatives have been introduced or are in development (Fig. 1 ) 22 . In this work, we tested gapmers consisting of an oligodeoxynucleotide flanked by different BNA analogs to determine their ability to elicit RNase H- and RNase P-mediated mRNA cleavage. Our results showed that gapmers composed of a stretch of LNA residues flanking an oligodeoxynucleotide are most efficient in eliciting degradation by both RNases. Furthermore, we showed that they can also reduce gene expression by steric hindrance depending on the location of the complementary region in the target mRNA. Results Previous comprehensive studies with varied analogs and configurations demonstrated that gapmers consisting of a short string of deoxyribonucleotides flanked by LNA residues in specific configurations were effective EGSs 26 – 28 . Building on that information, we designed a series of isosequential gapmers incorporating the currently available BNA analog variations (Table 1 and Fig. 1 ). The gapmers are complementary to a region of the aac(6')-Ib gene that was first identified as available for pairing with antisense oligoribonucleotides and elicit RNase P activity (region A, identified in red in Fig. 2 ) 29 , 30 . The gapmers used had the LNA 5 -DNA 8 -LNA 4 configuration, which was previously shown to be the most effective in eliciting mRNA cleavage by RNase P and inhibiting expression of aac(6')-Ib in a recent study comparing multiple configurations 26 . All gapmers used in this study were designed to include the sequence ACCA at the 3ʹ-end to enhance substrate recognition by RNase P. This sequence interacts with the complementary UGG sequence within the M1 RNA P15-loop 31 . Table 1 Oligonucleotides Name Sequence Chemistry M1 amplicon F TTGTAATACGACTCACTATAGGGGAAG DNA M1 amplicon R AGGTGAAACTGACCGATAAG DNA aac(6’)-Ib mRNA F GCAAGCTT TAATACGACTCACTATAG CATGAGACAATAACCCTGATAAATGCTTC DNA aac(6’)-Ib mRNA R GTTTAACGTTTGACATGAGGGC DNA RNAA rCrGrArTrArTrGrArGrArTrCrGrArCrCrA RNA DNAA CGATATGAGATCGACCA DNA LDAA [ L C][ L G][ L A][ L T][ L A]TGAGATCG[ L A][ L C][ L C][ L A] LNA 5 -DNA 8 -LNA 4 BDAA [ B C][ B G][ B A][ B T][ B A]TGAGATCG[ B A][ B C][ B C][ B A] BNA 5 -DNA 8 -BNA 4 EDAA [ E C][ E G][ E A][ E T][ E A]TGAGATCG[ E A][ E C][ E C][ E A] cET 5 -DNA 8 -cET 4 MDAA [ M C][ M G][ M A][ M T][ M A]TGAGATCG[ M A][ M C][ M C][ M A] cMOE 5 -DNA 8 -cMOE 4 LDAR [ L G][ L C][ L T][ L G][ L A]CTGAAATG[ L A][ L C][ L C][ L A] LNA 5 -DNA 8 -LNA 4 DNAN1 ATACTCATACTCTTCCT DNA DNAN2 AATGTTGAATACTCATA DNA DNAN3 TGGAAATGTTGAATACT DNA LDAN1 [ L A] [ L T] [ L A] [ L C] [ L T]CATACTCT[ L T] [ L C] [ L C] [ L T] LNA 5 -DNA 8 -LNA 4 The cleavage of the aac(6')-Ib mRNA was assessed in the presence of RNase P or RNase H using the gapmers constructed with different BNAs (Table 1 ). Figure 3 shows that RNase H exhibited activity with all gapmers tested. Similar levels of cleavage were observed when using LNA-, cMOE-, and cET-containing gapmers (LDAA, MDAA, and EDAA). A lower activity was found in the case of BDAA, the BNA NC -containing gapmer (Fig. 3 ). Conversely, significant cleavage by RNase P was observed only with the LDAA gapmer, which elicited complete mRNA degradation during the incubation period (Fig. 3 ). In all cases, including those lacking RNase P, we observed an approximate 290-nucleotide band of unknown origin present in the original sample. This band has been observed previously and is most likely a secondary transcription product generated during the synthesis of the aac(6')-Ib mRNA. The results of these assays demonstrate that hybrid antisense analogs with an appropriate chemical structure can act as DNA or RNA analogs, effectively generating appropriate substrates for RNase H and RNase P, respectively. Furthermore, in the case of LNA-containing gapmers, the compound could mimic both DNA or RNA when in duplex with the complementary sequence of the target mRNA and generate substrates for RNase H and RNase P. This dual activity could enhance antisense efficacy by designing molecules that recruit both RNase H and RNase P to degrade the target mRNA. To assess the correlation between target mRNA degradation in enzymatic assays and inhibition of AAC(6')-Ib protein synthesis, we performed experiments using coupled transcription–translation reactions in a cell lysate or a reconstituted system. This approach permits sidestepping the limitations of cell penetration by the antisense compounds. The cell lysates contain endogenous RNase H and RNase P, whereas the reconstituted extract lacks both enzymes. Reactions conducted in a cell lysate supplemented with the recombinant plasmid pAMND201, which carries aac(6')-Ib , resulted in robust expression of the AAC(6')-Ib protein (Fig. 4 A). The addition of the LDAA oligomer inhibited expression in a dose-dependent manner. In contrast, a control gapmer, LDAR, with the same chemical configuration but a random nucleotide sequence, had no effect (Fig. 4 A). In a second assay, coupled transcription–translation was performed using the reconstituted system. As shown in Fig. 4 B, the addition of LDAA did not interfere with AAC(6')-Ib expression. Expression levels were comparable to those observed in reactions without antisense added or with LDAR, indicating that in the absence of RNase H and RNase P, LDAA has no inhibitory effect. This result ruled out steric hindrance, suggesting that mRNA cleavage is the only LDAA mechanism of inhibition of aac(6')-Ib expression when the antisense molecule targets region A. The absence of a steric hindrance effect when targeting region A prompted us to evaluate the impact of antisense molecules directed at regions encompassing or adjacent to the binding site (RBS), highlighted in green in Fig. 4 B. Previous studies have shown that antisense molecules of a different chemical nature than those tested here, complementary to sequences within or near the RBS or translation start site, act by preventing binding and assembly of the ribosome 3 , 32 . Coupled transcription–translation reactions using the reconstituted system showed that an oligodeoxynucleotide complementary to a region including the RBS (DNAN1, Fig. 2 ) inhibited aac(6')-Ib expression (Fig. 4 C). The inhibitory effect decreased as the sequence targeted by the antisense molecule was shifted farther from the RBS (DNAN2 and DNAN3; Figs. 2 and 4 C), indicating that the target location on the mRNA is critical for determining both the mechanism and the extent of inhibition. A gapmer isosequential to DNAN1, LDAN1, was tested in the reconstituted system, and, unlike those targeting region A, there was strong inhibition by steric hindrance (Fig. 4 C). As expected, a gapmer with a random nucleotide sequence had no effect on translation (Fig. 4 C). These results demonstrate that gapmers composed of LNA residues flanking an oligodeoxyribonucleotide, in the configuration tested here, can interfere with gene expression through any of the three mechanisms examined, depending on the location of the complementary region within the target mRNA. Discussion Antisense inhibition of gene expression has been investigated as the basis of a therapeutic strategy for several decades with limited success. Aside from fomivirsen, an antiviral antisense agent that inhibits replication of human cytomegalovirus, approved for clinical use in 1998 but later discontinued for commercial reasons 33 , 34 , antisense medicines did not reach the market until the second decade of the twenty-first century. Moreover, those approved or currently in the pipeline are intended primarily for diseases other than bacterial infections 1 , 3 . Ongoing efforts to develop antisense drugs for bacterial pathogens include strategies aimed at either essential genes, functioning as actual antibiotics, or resistance genes, serving as adjuvants to existing antibiotics 3 . The main mechanisms of antisense-mediated inhibition explored to date involve either steric hindrance or recruitment of endogenous ribonucleases such as RNase H or RNase P. When inhibition is achieved via RNase P-mediated cleavage of the target mRNA, the approach is referred to as EGS technology. Because resistance to nucleases is a requirement for viable antisense drugs, several groups have studied the action of oligonucleotide analogs. Peptide nucleic acids and phosphorodiamidate morpholino oligomers have been used to inhibit bacterial growth, most probably by steric hindrance 35 – 37 . Attempts to design EGSs composed partially or entirely of analogs have generally been unsuccessful, except for gapmers consisting of an oligodeoxynucleotide flanked by LNA residues 28 . In particular, gapmers with LNA 5 -DNA 8 -LNA 4 configuration demonstrated the highest activity in the limited tests performed to date 26 , 27 . LNAs were the first of the BNA family of analogs, characterized by a methylene bridge between the 2′-oxygen and the 4′-carbon of the ribose ring. The development of additional BNA variants permitted us to build on this finding, assessing the activity of other gapmers with identical configuration. The goal of the study was to identify gapmers capable of eliciting target mRNA degradation through the recruitment of both RNase H and RNase P. While all the gapmers tested promoted RNase H-mediated cleavage, only the LNA-containing gapmer induced substantial RNase P-mediated degradation of the aac(6')-Ib mRNA. This dual activity of LDAA, eliciting both RNase H and RNase P cleavage to act on the target transcript, was a novel finding, underscoring its potential as a potent antisense inhibitor of gene expression. Given that the recruitment of endogenous RNase P by EGS molecules is the basis of EGS technology, our findings with the LNA 5 -DNA 8 -LNA 4 gapmer suggest a promising extension of this approach. We propose the extended methodology, named EGS-PH technology, that combines the actions of RNase P and RNase H to enhance mRNA degradation and gene silencing efficiency. The results also showed that small changes in the chemical structure of the BNA analog can result in substantial changes in activity. To circumvent the challenge of cellular uptake, we evaluated the activity of the LNA gapmer using a lysate-based cell-free coupled transcription–translation system. LDAA inhibited aac(6')-Ib expression in a dose-dependent manner. In contrast, a reconstituted in vitro system lacking RNase H and RNase P showed no inhibition, indicating that LDAA does not interfere with ribosome progression. On the other hand, a second LNA-containing gapmer targeting the RBS strongly inhibited expression via steric hindrance. These findings indicate that the gapmers studied here can act through different mechanisms depending on the region to which they are complementary. They also suggest that combining gapmers with distinct modes of action may lead to synergistic antisense effects. Although these assays are still in early development and require validation with additional targets, we are optimistic that strategies integrating EGS-PH technology with gapmers that act via steric hindrance hold significant promise for achieving robust and specific inhibition of undesirable gene expression, potentially opening new avenues for antisense-based therapeutic strategies. Methods Bacterial strains, plasmids, and oligonucleotides Escherichia coli TOP10 F - mcrA Δ( mrr-hsd RMS- mcr BC) Φ80 lac ZΔM15 Δ lac X74 rec A1 ara D139 Δ( ara-leu )7697 gal U gal K rps L(Str R ) end A1 nup G was used for recombinant cloning and plasmid isolation. Plasmid pJA', which includes the Escherichia coli rnpB gene downstream of the T7 promoter 38 , was used as template to generate the amplicon utilized to synthesize the M1 RNA component of RNase P. The primer sequences to generate the amplicon are shown in Table 1 . Plasmid pRHC5 was generated by inserting a DNA fragment containing the rnpA E. coli gene downstream of the T7 promoter in pT7-5 29 . This plasmid was used to express and purify the protein C5 component of RNase P. Plasmid DNA isolation was carried out using the QIAspin miniprep or midi kit (QIAGEN). The plasmid pAMND201, obtained by cloning a pJHCMW1 fragment containing the aac(6')-Ib gene (nucleotides 7111 to 7971, accession number AF479774) into the pCR2.1 vector, was used to synthesize the aac(6')-Ib mRNA in vitro (MEGAscript T7, Thermo Fisher Scientific) and for coupled in vitro transcription-translation. The nucleotide sequence of the primers to generate the amplicon to be inserted into the pCR2.1 cloning vector are shown in Table 1 . The sequence and configurations of the oligomers tested as antisense are shown in Table 1 . The analogs used were LNA, 2′-O-4′-methylene locked nucleic acid; cET, 2′-O,4′-ethyl bridge nucleic acid; cMOE, 2′-O,4′-methoxyethyl bridge nucleic acid; and BNA NC , 2′-O,4′-aminomethylene bridge nucleic acid (Fig. 1 ). Gapmers and oligoribonucleotides were purchased from BioSynthesis Inc. Oligodeoxynucleotides were purchased from IDT. RNase P preparation M1 RNA was synthesized in vitro using a commercial kit (MEGAshortscript T7, Thermo Fisher Scientific) following the recommendations of the supplier using an amplicon containing the rnpB gene under the control of a T7 promoter as a template 29 . The cofactor C5 protein was purified after expressing it from an E. coli strain that harbors a plasmid containing rnpA under the control of the T7 promoter (5). Both components were combined to generate the RNase P holoenzyme. RNase H was commercially available (NEBiolabs). In vitro RNase P and RNase H assays. RNase H and RNase P-mediated cleavage of aac(6')-Ib mRNA was carried out by preincubating 2 pmol aac(6')-Ib mRNA and 10 pmol of the antisense at 37°C for 30 min in a volume of 3 µl. Then, all 3 µl were mixed with a solution containing enzyme (0.25 pmol of M1 RNA, 70 pmol of C5 protein for RNase P or 1 unit RNase H) that had been preincubated at 37°C for 15 min in a final volume of 7 µl. The reactions were incubated at 37°C for the times indicated. Reactions were stopped by adding 2 volumes of loading buffer (15 mM Tris, 0.75 mM EDTA, 6 M urea). The products were analyzed using 6% denaturing Tris-borate EDTA-polyacrylamide gel electrophoresis. The gels were stained for 30 min in a 1x Biotium PAGE GelRed solution for 30 min with shaking at room temperature and visualized on an ultraviolet transilluminator. Coupled in vitro transcription-translation. Coupled transcription-translation reactions were carried out with the S30 T7 High-Yield Protein Expression System (Promega) and the PUREfrex 2.0 (GeneFrontier Corporation) as recommended by the supplier. The former system uses cell lysates, while the latter is a reconstituted cell-free protein synthesis system composed of amino acids, NTPs, tRNAs, RNA polymerase, translation factors, purified ribosomes, and other small-molecule compounds and proteins but lacking RNase H and RNase P 39 . The reactions were performed in the presence of plasmid pAMND201 DNA template with the additions indicated. The products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the synthesized AAC(6′)-Ib was subsequently detected by immunoblotting. After SDS-PAGE, the proteins were electrophoretically transferred to nitrocellulose paper using the Mini Trans-Blot cell (BioRad). The blots were rinsed in phosphate-buffered saline with Tween detergent (PBST) and blocked overnight at 4°C in PVDF Blocking Reagent (Toyobo). The membrane was then rinsed at room temperature in PBST for 15 min with shaking, rinsed twice in PBST for 5 min with shaking, and incubated for 1 hour at room temperature with anti-AAC(6')-Ib serum (10 µl of the adsorbed antiserum mixed with 10 ml Can Get Signal solution 1 (Toyobo)). After removal of the antiserum solution, the blots were washed three times with PBST for 5 min at room temperature with shaking. The blots were then incubated for 1 h at room temperature with a solution containing horseradish peroxidase-labeled protein A (Sigma, St. Louis, MO) in Can Get Signal solution 2 (Toyobo)). After removal from this solution, the blots were rinsed three times in PBST for 5 min at room temperature with shaking, followed by incubation in a solution containing SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) for 10 min with shaking. Chemiluminescence was detected on the Omega Lum™ C Imaging System 81-12110-00 (Gel Company). Declarations ACKNOWLEDGEMENTS This work was supported by Public Health Service grant 2R15AI047115 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. AUTHOR CONTRIBUTIONS Conceptualization, M.E.T.; formal analysis, A.J.M., M.S.R., and M.E.T.; funding acquisition, M.E.T.; methodology, A.J.M., K.P., J.L., M.S.R., and M.E.T.; resources, M.E.T.; writing—original draft preparation, M.E.T.; writing—review and editing, A.J.M., M.S.R., and M.E.T. All authors have read and agreed to the published version of the manuscript. DATA AVAILABILITY Bacterial strains used in this work are available upon request. COMPETING INTERESTS The author(s) declare no competing interests. References Crooke, S. T., Liang, X. H., Baker, B. F. & Crooke, R. M. Antisense technology: a review. J. Biol. Chem. 296 , 100416 (2021). https://doi.org/10.1016/j.jbc.2021.100416 Dhuri, K. et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med 9 , 2004 (2020). https://doi.org/10.3390/jcm9062004 Jani, S., Ramirez, M. S. & Tolmasky, M. E. Silencing antibiotic resistance with antisense oligonucleotides. Biomedicines 9 , 416 (2021). https://doi.org/10.3390/biomedicines9040416 Penchovsky, R., Georgieva, A. V., Dyakova, V., Traykovska, M. & Pavlova, N. Antisense and functional nucleic acids in rational drug development. Antibiotics (Basel) 13 , 221 (2024). https://doi.org/10.3390/antibiotics13030221 Rasmussen, L. C., Sperling-Petersen, H. U. & Mortensen, K. K. Hitting bacteria at the heart of the central dogma: sequence-specific inhibition. Microb Cell Fact 6 , 24 (2007). https://doi.org/10.1186/1475-2859-6-24 Sully, E. K. & Geller, B. L. Antisense antimicrobial therapeutics. Curr. Opin. Microbiol. 33 , 47-55 (2016). https://doi.org/10.1016/j.mib.2016.05.017 Ludolph, A. & Wiesenfarth, M. Tofersen and other antisense oligonucleotides in ALS. Ther. Adv. Neurol. Disord. 18 , 17562864251313915 (2025). https://doi.org/10.1177/17562864251313915 Rodrigues, M. & Yokota, T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol. Biol. 1828 , 31-55 (2018). https://doi.org/10.1007/978-1-4939-8651-4_2 Marasco, L. E. et al. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. Cell 185 , 2057-2070 e2015 (2022). https://doi.org/10.1016/j.cell.2022.04.031 Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X. H. Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20 , 427-453 (2021). https://doi.org/10.1038/s41573-021-00162-z Dinan, A. M. & Loftus, B. J. (Non-)translational medicine: targeting bacterial RNA. Front Genet 4 , 230 (2013). https://doi.org/10.3389/fgene.2013.00230 Goltermann, L. & Nielsen, P. E. PNA antisense targeting in bacteria: determination of antibacterial activity (MIC) of PNA-peptide conjugates. Methods Mol. Biol. 2105 , 231-239 (2020). https://doi.org/10.1007/978-1-0716-0243-0_14 Pifer, R. & Greenberg, D. E. Antisense antibacterial compounds. Transl. Res. 223 , 89-106 (2020). https://doi.org/10.1016/j.trsl.2020.06.001 Sully, E. K. et al. Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo. J. Antimicrob. Chemother. 72 , 782-790 (2017). https://doi.org/10.1093/jac/dkw476 Tolmasky, M. E. in Frontiers in Clinical Drug Research-Anti Infectives Vol. 1 (ed Atta-ur-Rhaman) Ch. 1, 1-27 (Bentham Books, 2017). Crooke, S. T. et al. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312 ( Pt 2) , 599-608 (1995). https://doi.org/10.1042/bj3120599 Kirsebom, L. A., Liu, F. & McClain, W. H. The discovery of a catalytic RNA within RNase P and its legacy. J. Biol. Chem. 300 , 107318 (2024). https://doi.org/10.1016/j.jbc.2024.107318 Davies-Sala, C., Soler-Bistue, A., Bonomo, R. A., Zorreguieta, A. & Tolmasky, M. E. External guide sequence technology: a path to development of novel antimicrobial therapeutics. Ann. N. Y. Acad. Sci. 1354 , 98-110 (2015). https://doi.org/10.1111/nyas.12755 Gopalan, V., Vioque, A. & Altman, S. RNase P: variations and uses. J. Biol. Chem. 277 , 6759-6762 (2002). https://doi.org/10.1074/jbc.R100067200 Agrawal, S. & Gait, M. in Advances in Nucleic Acid Therapeutics (eds S. Agrawal & M. Gait) 1-21 (Royal Society of Chemistry, 2019). Clave, G., Reverte, M., Vasseur, J. J. & Smietana, M. Modified internucleoside linkages for nuclease-resistant oligonucleotides. RSC Chem Biol 2 , 94-150 (2021). https://doi.org/10.1039/d0cb00136h Soler-Bistue, A., Zorreguieta, A. & Tolmasky, M. E. Bridged Nucleic Acids Reloaded. Molecules 24 , 2297 (2019). https://doi.org/10.3390/molecules24122297 Ramirez, M. S., Nikolaidis, N. & Tolmasky, M. E. Rise and dissemination of aminoglycoside resistance: the aac(6')-Ib paradigm. Front. Microbiol. 4 , 121 (2013). https://doi.org/10.3389/fmicb.2013.00121 Ramirez, M. S. & Tolmasky, M. E. Aminoglycoside modifying enzymes. Drug Resist Updat 13 , 151-171 (2010). https://doi.org/10.1016/j.drup.2010.08.003 d'Udekem d'Acoz, O. et al. Dynamics and quantitative contribution of the aminoglycoside 6'- N -acetyltransferase type Ib to amikacin resistance. mSphere 9 , e0078923 (2024). https://doi.org/10.1128/msphere.00789-23 Jackson, A. et al. Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes. Biol Methods Protoc 1 , bpw001 (2016). https://doi.org/10.1093/biomethods/bpw001 Jani, S. et al. Assessment of external guide sequences' (EGS) efficiency as inducers of RNase P-mediated cleavage of mRNA target molecules. Methods Mol. Biol. 1737 , 89-98 (2018). https://doi.org/10.1007/978-1-4939-7634-8_6 Soler Bistue, A. J. et al. Inhibition of aac(6')-Ib- mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria. Proc. Natl. Acad. Sci. U. S. A. 106 , 13230-13235 (2009). https://doi.org/10.1073/pnas.0906529106 Soler Bistue, A. J. et al. External guide sequences targeting the aac(6')-Ib mRNA induce inhibition of amikacin resistance. Antimicrob. Agents Chemother. 51 , 1918-1925 (2007). https://doi.org/10.1128/AAC.01500-06 Sarno, R., Ha, H., Weinsetel, N. & Tolmasky, M. E. Inhibition of aminoglycoside 6'- N -acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. Antimicrob. Agents Chemother. 47 , 3296-3304 (2003). Kirsebom, L. A. RNase P RNA mediated cleavage: substrate recognition and catalysis. Biochimie 89 , 1183-1194 (2007). https://doi.org/10.1016/j.biochi.2007.05.009 Pals, M. J., Lindberg, A. & Velema, W. A. Chemical strategies for antisense antibiotics. Chem. Soc. Rev. 53 , 11303-11320 (2024). https://doi.org/10.1039/d4cs00238e Alhamadani, F. et al. Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. Drug Metab. Dispos. 50 , 879-887 (2022). https://doi.org/10.1124/dmd.121.000418 Marwick, C. First "antisense" drug will treat CMV retinitis. JAMA 280 , 871 (1998). Nanayakkara, A. K., Moustafa, D. A., Pifer, R., Goldberg, J. B. & Greenberg, D. E. Sequence specificity defines the effectiveness of PPMOs targeting Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 67 , e0024523 (2023). https://doi.org/10.1128/aac.00245-23 Kim, S. K., Lee, J. B., Lee, H. T. & Yoon, J. W. Combined antimicrobial effect of two peptide nucleic acids against Staphylococcus aureus and S. pseudintermedius veterinary isolates. J. Vet. Sci. 25 , e12 (2024). https://doi.org/10.4142/jvs.23265 Kim, S. K., Lee, J. B., Lee, H. T., Han, D. & Yoon, J. W. Development of antisense peptide-peptide nucleic acids against fluoroquinolone-resistant Escherichia coli . J. Antimicrob. Chemother. 78 , 2052-2060 (2023). https://doi.org/10.1093/jac/dkad203 Vioque, A., Arnez, J. & Altman, S. Protein-RNA interactions in the RNase P holoenzyme from Escherichia coli . J. Mol. Biol. 202 , 835-848 (1988). https://doi.org/10.1016/0022-2836(88)90562-1 Shimizu, Y. et al. Cell-free translation reconstituted with purified components. Nat. Biotechnol. 19 , 751-755 (2001). https://doi.org/10.1038/90802 Additional Declarations No competing interests reported. Supplementary Files Supplementarymaterials.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7390173","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":508137813,"identity":"725f5490-313d-45c7-bdc7-5075e405e201","order_by":0,"name":"Angel J. Magaña","email":"","orcid":"","institution":"California State University Fullerton","correspondingAuthor":false,"prefix":"","firstName":"Angel","middleName":"J.","lastName":"Magaña","suffix":""},{"id":508137815,"identity":"62f978fd-4ffe-43d9-8547-c9631c1b8fab","order_by":1,"name":"Kimberly Phan","email":"","orcid":"","institution":"California State University Fullerton","correspondingAuthor":false,"prefix":"","firstName":"Kimberly","middleName":"","lastName":"Phan","suffix":""},{"id":508137817,"identity":"b77d34e2-6f88-4116-a672-4fb0e2a21cd4","order_by":2,"name":"Jesse Lopez","email":"","orcid":"","institution":"California State University Fullerton","correspondingAuthor":false,"prefix":"","firstName":"Jesse","middleName":"","lastName":"Lopez","suffix":""},{"id":508137820,"identity":"83df4934-0f81-4de6-ad9f-4c1f3e17885f","order_by":3,"name":"Maria S. Ramirez","email":"","orcid":"","institution":"California State University Fullerton","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"S.","lastName":"Ramirez","suffix":""},{"id":508137822,"identity":"71c86108-202e-4df1-af9f-bb807ae3d0ab","order_by":4,"name":"Marcelo E. Tolmasky","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8klEQVRIiWNgGAWjYHACxgNAwoCBvfEBw4MCmCAbHg1AOYgWnsMGDAkGDAw8xGuRSCZSi+785gOHbtTUGRvcfMwmkWBgk2/P3nuA4UPZYZxazI6xJRzOOXbYzOB2MkhLmmUPz7kExhnn8GnhMTicw3bAxuB2/jGglsMGPBI5Bsy8bYS0/KuzMbh5GGTLf4iWv4S05LYxmxncYAZpOQDRwohXS1rC4dy+w8aSZ5KZLRIMkg14zpwxONhzLh23lsOHDz7O+VZn2Hf8MOONDxV2BuztPYYPfpRZ49QCBwoHkDgHcChCBfINRCkbBaNgFIyCkQgALvVXJI5popcAAAAASUVORK5CYII=","orcid":"","institution":"California State University Fullerton","correspondingAuthor":true,"prefix":"","firstName":"Marcelo","middleName":"E.","lastName":"Tolmasky","suffix":""}],"badges":[],"createdAt":"2025-08-17 03:23:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7390173/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7390173/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":90503087,"identity":"f62c84a8-10f3-4722-85d1-f3721dec93ed","added_by":"auto","created_at":"2025-09-03 12:07:08","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":296980,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChemical structures of ribonucleotide analogs. \u003c/strong\u003eLNA, 2′-O-4′-methylene locked nucleic acid; cET, 2′-O,4′-ethyl bridge nucleic acid; cMOE, 2′-O,4′-methoxyethyl bridge nucleic acid, BNA\u003csup\u003eNC\u003c/sup\u003e, 2′-O,4′-aminomethylene bridge nucleic acid.\u003c/p\u003e","description":"","filename":"FIGURE1SUBMITTED.png","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/71ba0f6176fde45d7ddeb6d7.png"},{"id":90503090,"identity":"9f677f97-d77e-4e87-a2cd-a31558b90350","added_by":"auto","created_at":"2025-09-03 12:07:08","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1078344,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eNucleotide sequences of the\u0026nbsp;\u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eaac\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e(\u003c/strong\u003e\u003cem\u003e\u003cstrong\u003e6′\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e)\u003c/strong\u003e\u003cem\u003e\u003cstrong\u003e-Ib\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026nbsp;mRNA and antisense oligomers.\u003c/strong\u003e Complete sequence of the coding strand corresponding to the mRNA used in this work showing the AAC(6′)-Ib\u003cem\u003e \u003c/em\u003eamino acid sequence, the Shine-Dalgarno (green), and the region A, accessible to interact with antisense oligomers (red) as described in Sarno et al. \u003csup\u003e30\u003c/sup\u003e. AS-A, general nucleotide sequence of oligomers used in this study.\u003c/p\u003e","description":"","filename":"FIGURE2SUBMITTED.png","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/71b925c3e6a30163b4379b84.png"},{"id":90504002,"identity":"777de8b8-d76c-4633-9941-e233106c966b","added_by":"auto","created_at":"2025-09-03 12:15:08","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":1527279,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eRNase H or RNase P cleavage of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eaac(6′)-Ib \u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003emRNA-oligonucleotide analog duplex.\u003c/strong\u003e The cleavage reactions were carried out as described in the Methods section. Reactions were stopped by adding 2 volumes of loading buffer (15 mM Tris, 0.75 mM EDTA, 6 M urea). The products were analyzed using 6% denaturing Tris-borate EDTA-polyacrylamide gel electrophoresis. The gels were stained at room temperature with shaking for 30 min in a 1x Biotium PAGE GelRed solution and visualized on an ultraviolet transilluminator. Incubation times were 0, 2, 4, 8, 15, 30, 60, 120, and 240 minutes (left to right lanes after the molecular size standards, loaded on the leftmost well). The numbers to the right identify the nature of the compounds: 1, uncleaved mRNA; 2, 3’-end cleavage product; 3, M1, RNA component of RNase P; 4, unidentified; 5, 5’-end cleavage product. The numbers to the left indicate the nucleotide lengths (nt) of the molecular size standards.\u003c/p\u003e","description":"","filename":"FIGURE3SUBMITTEDflat.png","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/4ac0a11ece569faa44100982.png"},{"id":90503092,"identity":"66dc4574-f69c-4cec-b1ef-f327a75d323d","added_by":"auto","created_at":"2025-09-03 12:07:08","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":716198,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eInhibition of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eaac(6')-Ib\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e expression.\u003c/strong\u003e In all cases, the template was plasmid pAMND201 DNA, which carries the \u003cem\u003eaac(6')-Ib \u003c/em\u003egene\u003cem\u003e.\u003c/em\u003eReactions were carried out as described in the Methods section and the protein was detected by western immunoblot. A. Coupled transcription–translation reactions using cell lysates in the presence of increasing concentrations of LDAA. Control reactions were carried out with no antisense (leftmost lane), with addition of LDAR, a gapmer with a random sequence (rightmost lane), or without template and antisense oligomers (next to the rightmost lane). B and C. Coupled transcription–translation reactions using a reconstituted system lacking RNase H and RNase P. B, the experimental reaction is shown in second from left lane, control lanes are reactions lacking antisense (leftmost lane), template and antisense second lane from the rightmost), or with the addition of LDAR (rightmost lane). C, reactions performed in the presence of various antisense molecules (10 μM), as indicated above each lane. The rightmost lane corresponds to a reaction were addition of template and antisense were omitted.\u003c/p\u003e","description":"","filename":"FIGURE4SUBMITTEDflat.png","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/8a73c4af72e024ef528d8b45.png"},{"id":91336421,"identity":"3eb0aa13-2b3b-4a6d-abb6-c4bcbc4a45e2","added_by":"auto","created_at":"2025-09-15 12:08:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4716165,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/99a78a7e-9cdc-40d2-96b6-9f6d75b53c3c.pdf"},{"id":90504269,"identity":"29bf725e-683a-412b-986a-6f414f4507ec","added_by":"auto","created_at":"2025-09-03 12:23:08","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":1609686,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarymaterials.docx","url":"https://assets-eu.researchsquare.com/files/rs-7390173/v1/f366a9bd1540a8968a5e0dcb.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAntisense technologies are a group of approaches designed to interfere with harmful biological processes by reducing the expression of target genes using complementary oligonucleotides or oligonucleotide analogs \u003csup\u003e\u003cspan additionalcitationids=\"CR2 CR3 CR4 CR5 CR6\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. In the case of eukaryotic systems, these technologies can also be utilized to modify splicing of pre-mRNA and modify expression or correct defects \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Although these technologies face numerous challenges, such as stability, toxicity, delivery, and cellular penetration, many antisense drugs have been introduced in the market, and many others are in development \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. However, most drugs approved or in advanced clinical trials do not target bacterial pathogens. Despite considerable past and ongoing efforts \u003csup\u003e\u003cspan additionalcitationids=\"CR12 CR13 CR14\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, developing effective antisense pharmacological tools against bacterial infections remains an unmet challenge \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Interference with gene expression mediated by antisense compounds can mostly occur by steric hindrance, where the antisense impedes the binding or progression of the ribosome along the mRNA or through eliciting cleavage of the target mRNA \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Various strategies to induce steric hindrance or mRNA degradation have been explored. Two particularly intensive research areas focus on turning off prokaryotic genes by promoting the degradation of the target mRNA through recruiting endogenous RNases like RNase H or RNase P \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. The former alternative takes advantage of the property of the endonuclease RNase H, an enzyme characterized by its ability to cleave RNA when it is in a duplex with DNA in a non-sequence-specific manner \u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. The latter utilizes the ribozyme RNase P, which, in conjunction with a protein cofactor, cleaves duplex RNA:RNA in a structure-specific but sequence-nonspecific manner \u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. In this case, the antisense molecule is known as \"external guide sequence\" (EGS), and the general approach is known as EGS technology \u003csup\u003e\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eViable antisense drugs must resist nucleases that could degrade them before reaching their target. This property can be achieved by constructing oligomers totally or partially composed of nucleotide analogs \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. However, the oligomers must retain their ability to bind the complementary sequence, and the endogenous enzyme must recognize the duplex as substrate. If RNase H is the intended cleavage agent, the analog must resemble DNA when interacting with the target. On the other hand, if the desired compound should behave as an EGS, i.e., cleavage occurs via RNase P digestion, the antisense bound to the target must resemble a duplex RNA:RNA with the appropriate structure. A way to improve the efficiency of antisense-mediated gene silencing could be to recruit both endogenous RNases to degrade the target mRNA.\u003c/p\u003e\u003cp\u003eTo test this possibility, we aimed to design oligonucleotide analogs capable of eliciting degradation of the target mRNA by both RNase H and RNase P. As a model, we used the \u003cem\u003eaac(6ʹ)-Ib\u003c/em\u003e gene, which encodes the aminoglycoside 6'-\u003cem\u003eN\u003c/em\u003e-acetyltransferase type Ib [AAC(6')-Ib]. This enzyme is responsible for the inactivation of amikacin in most amikacin-resistant Gram-negative bacteria \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. Inhibition of expression of \u003cem\u003eaac(6ʹ)-Ib\u003c/em\u003e would enable the use of amikacin and other aminoglycosides to treat severe multidrug-resistant infections \u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. Our previous research showed that hybrid oligomers containing bridge nucleic acid (BNA) and deoxyribonucleotide residues in a gapmer configuration were promising analogs for recruiting RNase P to cleave target mRNA molecules and turn off expression of bacterial genes \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Since the early development of the first bridge nucleic acid, known as locked nucleic acid (LNA), characterized by a methylene group linking the 2\u0026prime;-oxygen and the 4\u0026prime;-carbon of the ribose residue (2\u0026prime;-\u003cem\u003eO\u003c/em\u003e,4\u0026prime;-methylene-β-d-ribofuranosyl nucleotides), other BNA derivatives have been introduced or are in development (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eIn this work, we tested gapmers consisting of an oligodeoxynucleotide flanked by different BNA analogs to determine their ability to elicit RNase H- and RNase P-mediated mRNA cleavage. Our results showed that gapmers composed of a stretch of LNA residues flanking an oligodeoxynucleotide are most efficient in eliciting degradation by both RNases. Furthermore, we showed that they can also reduce gene expression by steric hindrance depending on the location of the complementary region in the target mRNA.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003ePrevious comprehensive studies with varied analogs and configurations demonstrated that gapmers consisting of a short string of deoxyribonucleotides flanked by LNA residues in specific configurations were effective EGSs \u003csup\u003e\u003cspan additionalcitationids=\"CR27\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. Building on that information, we designed a series of isosequential gapmers incorporating the currently available BNA analog variations (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The gapmers are complementary to a region of the \u003cem\u003eaac(6')-Ib\u003c/em\u003e gene that was first identified as available for pairing with antisense oligoribonucleotides and elicit RNase P activity (region A, identified in red in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) \u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. The gapmers used had the LNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e configuration, which was previously shown to be the most effective in eliciting mRNA cleavage by RNase P and inhibiting expression of \u003cem\u003eaac(6')-Ib\u003c/em\u003e in a recent study comparing multiple configurations \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. All gapmers used in this study were designed to include the sequence ACCA at the 3ʹ-end to enhance substrate recognition by RNase P. This sequence interacts with the complementary UGG sequence within the M1 RNA P15-loop \u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eOligonucleotides\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"3\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eName\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSequence\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eChemistry\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eM1 amplicon F\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTTGTAATACGACTCACTATAGGGGAAG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eM1 amplicon R\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAGGTGAAACTGACCGATAAG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cem\u003eaac(6\u0026rsquo;)-Ib\u003c/em\u003e mRNA F\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGCAAGCTT\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003eTAATACGACTCACTATAG\u003c/span\u003eCATGAGACAATAACCCTGATAAATGCTTC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cem\u003eaac(6\u0026rsquo;)-Ib\u003c/em\u003e mRNA R\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGTTTAACGTTTGACATGAGGGC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRNAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003erCrGrArTrArTrGrArGrArTrCrGrArCrCrA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eRNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDNAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCGATATGAGATCGACCA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLDAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eG][\u003csup\u003eL\u003c/sup\u003eA][\u003csup\u003eL\u003c/sup\u003eT][\u003csup\u003eL\u003c/sup\u003eA]TGAGATCG[\u003csup\u003eL\u003c/sup\u003eA][\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eA]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBDAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eB\u003c/sup\u003eC][\u003csup\u003eB\u003c/sup\u003eG][\u003csup\u003eB\u003c/sup\u003eA][\u003csup\u003eB\u003c/sup\u003eT][\u003csup\u003eB\u003c/sup\u003eA]TGAGATCG[\u003csup\u003eB\u003c/sup\u003eA][\u003csup\u003eB\u003c/sup\u003eC][\u003csup\u003eB\u003c/sup\u003eC][\u003csup\u003eB\u003c/sup\u003eA]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eBNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-BNA\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEDAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eE\u003c/sup\u003eC][\u003csup\u003eE\u003c/sup\u003eG][\u003csup\u003eE\u003c/sup\u003eA][\u003csup\u003eE\u003c/sup\u003eT][\u003csup\u003eE\u003c/sup\u003eA]TGAGATCG[\u003csup\u003eE\u003c/sup\u003eA][\u003csup\u003eE\u003c/sup\u003eC][\u003csup\u003eE\u003c/sup\u003eC][\u003csup\u003eE\u003c/sup\u003eA]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ecET\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-cET\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMDAA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eM\u003c/sup\u003eC][\u003csup\u003eM\u003c/sup\u003eG][\u003csup\u003eM\u003c/sup\u003eA][\u003csup\u003eM\u003c/sup\u003eT][\u003csup\u003eM\u003c/sup\u003eA]TGAGATCG[\u003csup\u003eM\u003c/sup\u003eA][\u003csup\u003eM\u003c/sup\u003eC][\u003csup\u003eM\u003c/sup\u003eC][\u003csup\u003eM\u003c/sup\u003eA]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ecMOE\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-cMOE\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLDAR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eL\u003c/sup\u003eG][\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eT][\u003csup\u003eL\u003c/sup\u003eG][\u003csup\u003eL\u003c/sup\u003eA]CTGAAATG[\u003csup\u003eL\u003c/sup\u003eA][\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eC][\u003csup\u003eL\u003c/sup\u003eA]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDNAN1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eATACTCATACTCTTCCT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDNAN2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAATGTTGAATACTCATA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDNAN3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTGGAAATGTTGAATACT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDNA\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLDAN1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[\u003csup\u003eL\u003c/sup\u003eA] [\u003csup\u003eL\u003c/sup\u003eT] [\u003csup\u003eL\u003c/sup\u003eA] [\u003csup\u003eL\u003c/sup\u003eC] [\u003csup\u003eL\u003c/sup\u003eT]CATACTCT[\u003csup\u003eL\u003c/sup\u003eT] [\u003csup\u003eL\u003c/sup\u003eC] [\u003csup\u003eL\u003c/sup\u003eC] [\u003csup\u003eL\u003c/sup\u003eT]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eThe cleavage of the \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA was assessed in the presence of RNase P or RNase H using the gapmers constructed with different BNAs (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e shows that RNase H exhibited activity with all gapmers tested. Similar levels of cleavage were observed when using LNA-, cMOE-, and cET-containing gapmers (LDAA, MDAA, and EDAA). A lower activity was found in the case of BDAA, the BNA\u003csup\u003eNC\u003c/sup\u003e-containing gapmer (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Conversely, significant cleavage by RNase P was observed only with the LDAA gapmer, which elicited complete mRNA degradation during the incubation period (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). In all cases, including those lacking RNase P, we observed an approximate 290-nucleotide band of unknown origin present in the original sample. This band has been observed previously and is most likely a secondary transcription product generated during the synthesis of the \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eThe results of these assays demonstrate that hybrid antisense analogs with an appropriate chemical structure can act as DNA or RNA analogs, effectively generating appropriate substrates for RNase H and RNase P, respectively. Furthermore, in the case of LNA-containing gapmers, the compound could mimic both DNA or RNA when in duplex with the complementary sequence of the target mRNA and generate substrates for RNase H and RNase P. This dual activity could enhance antisense efficacy by designing molecules that recruit both RNase H and RNase P to degrade the target mRNA.\u003c/p\u003e\u003cp\u003eTo assess the correlation between target mRNA degradation in enzymatic assays and inhibition of AAC(6')-Ib protein synthesis, we performed experiments using coupled transcription\u0026ndash;translation reactions in a cell lysate or a reconstituted system. This approach permits sidestepping the limitations of cell penetration by the antisense compounds. The cell lysates contain endogenous RNase H and RNase P, whereas the reconstituted extract lacks both enzymes. Reactions conducted in a cell lysate supplemented with the recombinant plasmid pAMND201, which carries \u003cem\u003eaac(6')-Ib\u003c/em\u003e, resulted in robust expression of the AAC(6')-Ib protein (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). The addition of the LDAA oligomer inhibited expression in a dose-dependent manner. In contrast, a control gapmer, LDAR, with the same chemical configuration but a random nucleotide sequence, had no effect (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). In a second assay, coupled transcription\u0026ndash;translation was performed using the reconstituted system. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB, the addition of LDAA did not interfere with AAC(6')-Ib expression. Expression levels were comparable to those observed in reactions without antisense added or with LDAR, indicating that in the absence of RNase H and RNase P, LDAA has no inhibitory effect. This result ruled out steric hindrance, suggesting that mRNA cleavage is the only LDAA mechanism of inhibition of \u003cem\u003eaac(6')-Ib\u003c/em\u003e expression when the antisense molecule targets region A.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eThe absence of a steric hindrance effect when targeting region A prompted us to evaluate the impact of antisense molecules directed at regions encompassing or adjacent to the binding site (RBS), highlighted in green in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB. Previous studies have shown that antisense molecules of a different chemical nature than those tested here, complementary to sequences within or near the RBS or translation start site, act by preventing binding and assembly of the ribosome \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Coupled transcription\u0026ndash;translation reactions using the reconstituted system showed that an oligodeoxynucleotide complementary to a region including the RBS (DNAN1, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) inhibited \u003cem\u003eaac(6')-Ib\u003c/em\u003e expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). The inhibitory effect decreased as the sequence targeted by the antisense molecule was shifted farther from the RBS (DNAN2 and DNAN3; Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e and \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC), indicating that the target location on the mRNA is critical for determining both the mechanism and the extent of inhibition. A gapmer isosequential to DNAN1, LDAN1, was tested in the reconstituted system, and, unlike those targeting region A, there was strong inhibition by steric hindrance (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). As expected, a gapmer with a random nucleotide sequence had no effect on translation (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). These results demonstrate that gapmers composed of LNA residues flanking an oligodeoxyribonucleotide, in the configuration tested here, can interfere with gene expression through any of the three mechanisms examined, depending on the location of the complementary region within the target mRNA.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eAntisense inhibition of gene expression has been investigated as the basis of a therapeutic strategy for several decades with limited success. Aside from fomivirsen, an antiviral antisense agent that inhibits replication of human cytomegalovirus, approved for clinical use in 1998 but later discontinued for commercial reasons \u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e, antisense medicines did not reach the market until the second decade of the twenty-first century. Moreover, those approved or currently in the pipeline are intended primarily for diseases other than bacterial infections \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Ongoing efforts to develop antisense drugs for bacterial pathogens include strategies aimed at either essential genes, functioning as actual antibiotics, or resistance genes, serving as adjuvants to existing antibiotics \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. The main mechanisms of antisense-mediated inhibition explored to date involve either steric hindrance or recruitment of endogenous ribonucleases such as RNase H or RNase P. When inhibition is achieved via RNase P-mediated cleavage of the target mRNA, the approach is referred to as EGS technology. Because resistance to nucleases is a requirement for viable antisense drugs, several groups have studied the action of oligonucleotide analogs. Peptide nucleic acids and phosphorodiamidate morpholino oligomers have been used to inhibit bacterial growth, most probably by steric hindrance \u003csup\u003e\u003cspan additionalcitationids=\"CR36\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. Attempts to design EGSs composed partially or entirely of analogs have generally been unsuccessful, except for gapmers consisting of an oligodeoxynucleotide flanked by LNA residues \u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. In particular, gapmers with LNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e configuration demonstrated the highest activity in the limited tests performed to date \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. LNAs were the first of the BNA family of analogs, characterized by a methylene bridge between the 2\u0026prime;-oxygen and the 4\u0026prime;-carbon of the ribose ring. The development of additional BNA variants permitted us to build on this finding, assessing the activity of other gapmers with identical configuration. The goal of the study was to identify gapmers capable of eliciting target mRNA degradation through the recruitment of both RNase H and RNase P. While all the gapmers tested promoted RNase H-mediated cleavage, only the LNA-containing gapmer induced substantial RNase P-mediated degradation of the \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA. This dual activity of LDAA, eliciting both RNase H and RNase P cleavage to act on the target transcript, was a novel finding, underscoring its potential as a potent antisense inhibitor of gene expression. Given that the recruitment of endogenous RNase P by EGS molecules is the basis of EGS technology, our findings with the LNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-LNA\u003csub\u003e4\u003c/sub\u003e gapmer suggest a promising extension of this approach. We propose the extended methodology, named EGS-PH technology, that combines the actions of RNase P and RNase H to enhance mRNA degradation and gene silencing efficiency. The results also showed that small changes in the chemical structure of the BNA analog can result in substantial changes in activity.\u003c/p\u003e\u003cp\u003eTo circumvent the challenge of cellular uptake, we evaluated the activity of the LNA gapmer using a lysate-based cell-free coupled transcription\u0026ndash;translation system. LDAA inhibited \u003cem\u003eaac(6')-Ib\u003c/em\u003e expression in a dose-dependent manner. In contrast, a reconstituted in vitro system lacking RNase H and RNase P showed no inhibition, indicating that LDAA does not interfere with ribosome progression. On the other hand, a second LNA-containing gapmer targeting the RBS strongly inhibited expression via steric hindrance. These findings indicate that the gapmers studied here can act through different mechanisms depending on the region to which they are complementary. They also suggest that combining gapmers with distinct modes of action may lead to synergistic antisense effects. Although these assays are still in early development and require validation with additional targets, we are optimistic that strategies integrating EGS-PH technology with gapmers that act via steric hindrance hold significant promise for achieving robust and specific inhibition of undesirable gene expression, potentially opening new avenues for antisense-based therapeutic strategies.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003eBacterial strains, plasmids, and oligonucleotides\u003c/h2\u003e\u003cp\u003e\u003cem\u003eEscherichia coli\u003c/em\u003e TOP10 F\u003csup\u003e-\u003c/sup\u003e \u003cem\u003emcrA\u003c/em\u003e Δ(\u003cem\u003emrr-hsd\u003c/em\u003eRMS-\u003cem\u003emcr\u003c/em\u003eBC) Φ80\u003cem\u003elac\u003c/em\u003eZΔM15 Δ\u003cem\u003elac\u003c/em\u003eX74 \u003cem\u003erec\u003c/em\u003eA1 \u003cem\u003eara\u003c/em\u003eD139 Δ(\u003cem\u003eara-leu\u003c/em\u003e)7697 \u003cem\u003egal\u003c/em\u003eU \u003cem\u003egal\u003c/em\u003eK \u003cem\u003erps\u003c/em\u003eL(Str\u003csup\u003eR\u003c/sup\u003e) \u003cem\u003eend\u003c/em\u003eA1 \u003cem\u003enup\u003c/em\u003eG was used for recombinant cloning and plasmid isolation. Plasmid pJA', which includes the \u003cem\u003eEscherichia coli rnpB\u003c/em\u003e gene downstream of the T7 promoter \u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e, was used as template to generate the amplicon utilized to synthesize the M1 RNA component of RNase P. The primer sequences to generate the amplicon are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Plasmid pRHC5 was generated by inserting a DNA fragment containing the \u003cem\u003ernpA E. coli\u003c/em\u003e gene downstream of the T7 promoter in pT7-5 \u003csup\u003e29\u003c/sup\u003e. This plasmid was used to express and purify the protein C5 component of RNase P. Plasmid DNA isolation was carried out using the QIAspin miniprep or midi kit (QIAGEN). The plasmid pAMND201, obtained by cloning a pJHCMW1 fragment containing the \u003cem\u003eaac(6')-Ib\u003c/em\u003e gene (nucleotides 7111 to 7971, accession number AF479774) into the pCR2.1 vector, was used to synthesize the \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA in vitro (MEGAscript T7, Thermo Fisher Scientific) and for coupled in vitro transcription-translation. The nucleotide sequence of the primers to generate the amplicon to be inserted into the pCR2.1 cloning vector are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. The sequence and configurations of the oligomers tested as antisense are shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. The analogs used were LNA, 2\u0026prime;-O-4\u0026prime;-methylene locked nucleic acid; cET, 2\u0026prime;-O,4\u0026prime;-ethyl bridge nucleic acid; cMOE, 2\u0026prime;-O,4\u0026prime;-methoxyethyl bridge nucleic acid; and BNA\u003csup\u003eNC\u003c/sup\u003e, 2\u0026prime;-O,4\u0026prime;-aminomethylene bridge nucleic acid (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Gapmers and oligoribonucleotides were purchased from BioSynthesis Inc. Oligodeoxynucleotides were purchased from IDT.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eRNase P preparation\u003c/h3\u003e\n\u003cp\u003eM1 RNA was synthesized in vitro using a commercial kit (MEGAshortscript T7, Thermo Fisher Scientific) following the recommendations of the supplier using an amplicon containing the \u003cem\u003ernpB\u003c/em\u003e gene under the control of a T7 promoter as a template \u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. The cofactor C5 protein was purified after expressing it from an \u003cem\u003eE. coli\u003c/em\u003e strain that harbors a plasmid containing \u003cem\u003ernpA\u003c/em\u003e under the control of the T7 promoter (5). Both components were combined to generate the RNase P holoenzyme. RNase H was commercially available (NEBiolabs).\u003c/p\u003e\u003cp\u003e\u003cb\u003eIn vitro RNase P and RNase H assays.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eRNase H and RNase P-mediated cleavage of \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA was carried out by preincubating 2 pmol \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA and 10 pmol of the antisense at 37\u0026deg;C for 30 min in a volume of 3 \u0026micro;l. Then, all 3 \u0026micro;l were mixed with a solution containing enzyme (0.25 pmol of M1 RNA, 70 pmol of C5 protein for RNase P or 1 unit RNase H) that had been preincubated at 37\u0026deg;C for 15 min in a final volume of 7 \u0026micro;l. The reactions were incubated at 37\u0026deg;C for the times indicated. Reactions were stopped by adding 2 volumes of loading buffer (15 mM Tris, 0.75 mM EDTA, 6 M urea). The products were analyzed using 6% denaturing Tris-borate EDTA-polyacrylamide gel electrophoresis. The gels were stained for 30 min in a 1x Biotium PAGE GelRed solution for 30 min with shaking at room temperature and visualized on an ultraviolet transilluminator.\u003c/p\u003e\u003cp\u003e\u003cb\u003eCoupled in vitro transcription-translation.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eCoupled transcription-translation reactions were carried out with the S30 T7 High-Yield Protein Expression System (Promega) and the PUREfrex 2.0 (GeneFrontier Corporation) as recommended by the supplier. The former system uses cell lysates, while the latter is a reconstituted cell-free protein synthesis system composed of amino acids, NTPs, tRNAs, RNA polymerase, translation factors, purified ribosomes, and other small-molecule compounds and proteins but lacking RNase H and RNase P \u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. The reactions were performed in the presence of plasmid pAMND201 DNA template with the additions indicated. The products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the synthesized AAC(6\u0026prime;)-Ib was subsequently detected by immunoblotting. After SDS-PAGE, the proteins were electrophoretically transferred to nitrocellulose paper using the Mini Trans-Blot cell (BioRad). The blots were rinsed in phosphate-buffered saline with Tween detergent (PBST) and blocked overnight at 4\u0026deg;C in PVDF Blocking Reagent (Toyobo). The membrane was then rinsed at room temperature in PBST for 15 min with shaking, rinsed twice in PBST for 5 min with shaking, and incubated for 1 hour at room temperature with anti-AAC(6')-Ib serum (10 \u0026micro;l of the adsorbed antiserum mixed with 10 ml Can Get Signal solution 1 (Toyobo)). After removal of the antiserum solution, the blots were washed three times with PBST for 5 min at room temperature with shaking. The blots were then incubated for 1 h at room temperature with a solution containing horseradish peroxidase-labeled protein A (Sigma, St. Louis, MO) in Can Get Signal solution 2 (Toyobo)). After removal from this solution, the blots were rinsed three times in PBST for 5 min at room temperature with shaking, followed by incubation in a solution containing SuperSignal\u0026trade; West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) for 10 min with shaking. Chemiluminescence was detected on the Omega Lum\u0026trade; C Imaging System 81-12110-00 (Gel Company).\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eACKNOWLEDGEMENTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by Public Health Service grant 2R15AI047115 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHOR CONTRIBUTIONS\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceptualization, M.E.T.; formal analysis, A.J.M., M.S.R., and M.E.T.; funding acquisition, M.E.T.; methodology, A.J.M., K.P.,\u0026nbsp;J.L., M.S.R., and M.E.T.; resources, M.E.T.; writing\u0026mdash;original draft preparation, M.E.T.; writing\u0026mdash;review and editing, A.J.M., M.S.R., and M.E.T. All authors have read and agreed to the published version of the manuscript.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDATA AVAILABILITY\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBacterial strains used in this work are available upon request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCOMPETING INTERESTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe author(s) declare no competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eCrooke, S. T., Liang, X. H., Baker, B. F. \u0026amp; Crooke, R. M. Antisense technology: a review. \u003cem\u003eJ. Biol. Chem.\u003c/em\u003e \u003cstrong\u003e296\u003c/strong\u003e, 100416 (2021). https://doi.org/10.1016/j.jbc.2021.100416\u003c/li\u003e\n\u003cli\u003eDhuri, K.\u003cem\u003e et al.\u003c/em\u003e Antisense oligonucleotides: an emerging area in drug discovery and development. \u003cem\u003eJ Clin Med\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 2004 (2020). https://doi.org/10.3390/jcm9062004\u003c/li\u003e\n\u003cli\u003eJani, S., Ramirez, M. S. \u0026amp; Tolmasky, M. E. Silencing antibiotic resistance with antisense oligonucleotides. \u003cem\u003eBiomedicines\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 416 (2021). https://doi.org/10.3390/biomedicines9040416\u003c/li\u003e\n\u003cli\u003ePenchovsky, R., Georgieva, A. V., Dyakova, V., Traykovska, M. \u0026amp; Pavlova, N. Antisense and functional nucleic acids in rational drug development. \u003cem\u003eAntibiotics (Basel)\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 221 (2024). https://doi.org/10.3390/antibiotics13030221\u003c/li\u003e\n\u003cli\u003eRasmussen, L. C., Sperling-Petersen, H. U. \u0026amp; Mortensen, K. K. Hitting bacteria at the heart of the central dogma: sequence-specific inhibition. \u003cem\u003eMicrob Cell Fact\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 24 (2007). https://doi.org/10.1186/1475-2859-6-24\u003c/li\u003e\n\u003cli\u003eSully, E. K. \u0026amp; Geller, B. L. Antisense antimicrobial therapeutics. \u003cem\u003eCurr. Opin. Microbiol.\u003c/em\u003e \u003cstrong\u003e33\u003c/strong\u003e, 47-55 (2016). https://doi.org/10.1016/j.mib.2016.05.017\u003c/li\u003e\n\u003cli\u003eLudolph, A. \u0026amp; Wiesenfarth, M. Tofersen and other antisense oligonucleotides in ALS. \u003cem\u003eTher. Adv. Neurol. Disord.\u003c/em\u003e \u003cstrong\u003e18\u003c/strong\u003e, 17562864251313915 (2025). https://doi.org/10.1177/17562864251313915\u003c/li\u003e\n\u003cli\u003eRodrigues, M. \u0026amp; Yokota, T. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. \u003cem\u003eMethods Mol. Biol.\u003c/em\u003e \u003cstrong\u003e1828\u003c/strong\u003e, 31-55 (2018). https://doi.org/10.1007/978-1-4939-8651-4_2\u003c/li\u003e\n\u003cli\u003eMarasco, L. E.\u003cem\u003e et al.\u003c/em\u003e Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. \u003cem\u003eCell\u003c/em\u003e \u003cstrong\u003e185\u003c/strong\u003e, 2057-2070 e2015 (2022). https://doi.org/10.1016/j.cell.2022.04.031\u003c/li\u003e\n\u003cli\u003eCrooke, S. T., Baker, B. F., Crooke, R. M. \u0026amp; Liang, X. H. Antisense technology: an overview and prospectus. \u003cem\u003eNat Rev Drug Discov\u003c/em\u003e \u003cstrong\u003e20\u003c/strong\u003e, 427-453 (2021). https://doi.org/10.1038/s41573-021-00162-z\u003c/li\u003e\n\u003cli\u003eDinan, A. M. \u0026amp; Loftus, B. J. (Non-)translational medicine: targeting bacterial RNA. \u003cem\u003eFront Genet\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, 230 (2013). https://doi.org/10.3389/fgene.2013.00230\u003c/li\u003e\n\u003cli\u003eGoltermann, L. \u0026amp; Nielsen, P. E. PNA antisense targeting in bacteria: determination of antibacterial activity (MIC) of PNA-peptide conjugates. \u003cem\u003eMethods Mol. Biol.\u003c/em\u003e \u003cstrong\u003e2105\u003c/strong\u003e, 231-239 (2020). https://doi.org/10.1007/978-1-0716-0243-0_14\u003c/li\u003e\n\u003cli\u003ePifer, R. \u0026amp; Greenberg, D. E. Antisense antibacterial compounds. \u003cem\u003eTransl. Res.\u003c/em\u003e \u003cstrong\u003e223\u003c/strong\u003e, 89-106 (2020). https://doi.org/10.1016/j.trsl.2020.06.001\u003c/li\u003e\n\u003cli\u003eSully, E. K.\u003cem\u003e et al.\u003c/em\u003e Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo. \u003cem\u003eJ. Antimicrob. Chemother.\u003c/em\u003e \u003cstrong\u003e72\u003c/strong\u003e, 782-790 (2017). https://doi.org/10.1093/jac/dkw476\u003c/li\u003e\n\u003cli\u003eTolmasky, M. E. in \u003cem\u003eFrontiers in Clinical Drug Research-Anti Infectives\u003c/em\u003e Vol. 1 (ed Atta-ur-Rhaman) Ch. 1, 1-27 (Bentham Books, 2017).\u003c/li\u003e\n\u003cli\u003eCrooke, S. T.\u003cem\u003e et al.\u003c/em\u003e Kinetic characteristics of \u003cem\u003eEscherichia coli \u003c/em\u003eRNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. \u003cem\u003eBiochem. J.\u003c/em\u003e \u003cstrong\u003e312 ( Pt 2)\u003c/strong\u003e, 599-608 (1995). https://doi.org/10.1042/bj3120599\u003c/li\u003e\n\u003cli\u003eKirsebom, L. A., Liu, F. \u0026amp; McClain, W. H. The discovery of a catalytic RNA within RNase P and its legacy. \u003cem\u003eJ. Biol. Chem.\u003c/em\u003e \u003cstrong\u003e300\u003c/strong\u003e, 107318 (2024). https://doi.org/10.1016/j.jbc.2024.107318\u003c/li\u003e\n\u003cli\u003eDavies-Sala, C., Soler-Bistue, A., Bonomo, R. A., Zorreguieta, A. \u0026amp; Tolmasky, M. E. External guide sequence technology: a path to development of novel antimicrobial therapeutics. \u003cem\u003eAnn. N. Y. Acad. Sci.\u003c/em\u003e \u003cstrong\u003e1354\u003c/strong\u003e, 98-110 (2015). https://doi.org/10.1111/nyas.12755\u003c/li\u003e\n\u003cli\u003eGopalan, V., Vioque, A. \u0026amp; Altman, S. RNase P: variations and uses. \u003cem\u003eJ. Biol. Chem.\u003c/em\u003e \u003cstrong\u003e277\u003c/strong\u003e, 6759-6762 (2002). https://doi.org/10.1074/jbc.R100067200\u003c/li\u003e\n\u003cli\u003eAgrawal, S. \u0026amp; Gait, M. in \u003cem\u003eAdvances in Nucleic Acid Therapeutics\u003c/em\u003e (eds S. Agrawal \u0026amp; M. Gait) 1-21 (Royal Society of Chemistry, 2019).\u003c/li\u003e\n\u003cli\u003eClave, G., Reverte, M., Vasseur, J. J. \u0026amp; Smietana, M. Modified internucleoside linkages for nuclease-resistant oligonucleotides. \u003cem\u003eRSC Chem Biol\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e, 94-150 (2021). https://doi.org/10.1039/d0cb00136h\u003c/li\u003e\n\u003cli\u003eSoler-Bistue, A., Zorreguieta, A. \u0026amp; Tolmasky, M. E. Bridged Nucleic Acids Reloaded. \u003cem\u003eMolecules\u003c/em\u003e \u003cstrong\u003e24\u003c/strong\u003e, 2297 (2019). https://doi.org/10.3390/molecules24122297\u003c/li\u003e\n\u003cli\u003eRamirez, M. S., Nikolaidis, N. \u0026amp; Tolmasky, M. E. Rise and dissemination of aminoglycoside resistance: the \u003cem\u003eaac(6\u0026apos;)-Ib\u003c/em\u003e paradigm. \u003cem\u003eFront. Microbiol.\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, 121 (2013). https://doi.org/10.3389/fmicb.2013.00121\u003c/li\u003e\n\u003cli\u003eRamirez, M. S. \u0026amp; Tolmasky, M. E. Aminoglycoside modifying enzymes. \u003cem\u003eDrug Resist Updat\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 151-171 (2010). https://doi.org/10.1016/j.drup.2010.08.003\u003c/li\u003e\n\u003cli\u003ed\u0026apos;Udekem d\u0026apos;Acoz, O.\u003cem\u003e et al.\u003c/em\u003e Dynamics and quantitative contribution of the aminoglycoside 6\u0026apos;-\u003cem\u003eN\u003c/em\u003e-acetyltransferase type Ib to amikacin resistance. \u003cem\u003emSphere\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, e0078923 (2024). https://doi.org/10.1128/msphere.00789-23\u003c/li\u003e\n\u003cli\u003eJackson, A.\u003cem\u003e et al.\u003c/em\u003e Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes. \u003cem\u003eBiol Methods Protoc\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e, bpw001 (2016). https://doi.org/10.1093/biomethods/bpw001\u003c/li\u003e\n\u003cli\u003eJani, S.\u003cem\u003e et al.\u003c/em\u003e Assessment of external guide sequences\u0026apos; (EGS) efficiency as inducers of RNase P-mediated cleavage of mRNA target molecules. \u003cem\u003eMethods Mol. Biol.\u003c/em\u003e \u003cstrong\u003e1737\u003c/strong\u003e, 89-98 (2018). https://doi.org/10.1007/978-1-4939-7634-8_6\u003c/li\u003e\n\u003cli\u003eSoler Bistue, A. J.\u003cem\u003e et al.\u003c/em\u003e Inhibition of \u003cem\u003eaac(6\u0026apos;)-Ib-\u003c/em\u003emediated amikacin resistance by nuclease-resistant external guide sequences in bacteria. \u003cem\u003eProc. Natl. Acad. Sci. U. S. A.\u003c/em\u003e \u003cstrong\u003e106\u003c/strong\u003e, 13230-13235 (2009). https://doi.org/10.1073/pnas.0906529106\u003c/li\u003e\n\u003cli\u003eSoler Bistue, A. J.\u003cem\u003e et al.\u003c/em\u003e External guide sequences targeting the \u003cem\u003eaac(6\u0026apos;)-Ib\u003c/em\u003e mRNA induce inhibition of amikacin resistance. \u003cem\u003eAntimicrob. Agents Chemother.\u003c/em\u003e \u003cstrong\u003e51\u003c/strong\u003e, 1918-1925 (2007). https://doi.org/10.1128/AAC.01500-06\u003c/li\u003e\n\u003cli\u003eSarno, R., Ha, H., Weinsetel, N. \u0026amp; Tolmasky, M. E. Inhibition of aminoglycoside 6\u0026apos;-\u003cem\u003eN\u003c/em\u003e-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. \u003cem\u003eAntimicrob. Agents Chemother.\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 3296-3304 (2003). \u003c/li\u003e\n\u003cli\u003eKirsebom, L. A. RNase P RNA mediated cleavage: substrate recognition and catalysis. \u003cem\u003eBiochimie\u003c/em\u003e \u003cstrong\u003e89\u003c/strong\u003e, 1183-1194 (2007). https://doi.org/10.1016/j.biochi.2007.05.009\u003c/li\u003e\n\u003cli\u003ePals, M. J., Lindberg, A. \u0026amp; Velema, W. A. Chemical strategies for antisense antibiotics. \u003cem\u003eChem. Soc. Rev.\u003c/em\u003e \u003cstrong\u003e53\u003c/strong\u003e, 11303-11320 (2024). https://doi.org/10.1039/d4cs00238e\u003c/li\u003e\n\u003cli\u003eAlhamadani, F.\u003cem\u003e et al.\u003c/em\u003e Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. \u003cem\u003eDrug Metab. Dispos.\u003c/em\u003e \u003cstrong\u003e50\u003c/strong\u003e, 879-887 (2022). https://doi.org/10.1124/dmd.121.000418\u003c/li\u003e\n\u003cli\u003eMarwick, C. First \u0026quot;antisense\u0026quot; drug will treat CMV retinitis. \u003cem\u003eJAMA\u003c/em\u003e \u003cstrong\u003e280\u003c/strong\u003e, 871 (1998). \u003c/li\u003e\n\u003cli\u003eNanayakkara, A. K., Moustafa, D. A., Pifer, R., Goldberg, J. B. \u0026amp; Greenberg, D. E. Sequence specificity defines the effectiveness of PPMOs targeting \u003cem\u003ePseudomonas aeruginosa\u003c/em\u003e. \u003cem\u003eAntimicrob. Agents Chemother.\u003c/em\u003e \u003cstrong\u003e67\u003c/strong\u003e, e0024523 (2023). https://doi.org/10.1128/aac.00245-23\u003c/li\u003e\n\u003cli\u003eKim, S. K., Lee, J. B., Lee, H. T. \u0026amp; Yoon, J. W. Combined antimicrobial effect of two peptide nucleic acids against \u003cem\u003eStaphylococcus aureus\u003c/em\u003e and \u003cem\u003eS. pseudintermedius\u003c/em\u003e veterinary isolates. \u003cem\u003eJ. Vet. Sci.\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, e12 (2024). https://doi.org/10.4142/jvs.23265\u003c/li\u003e\n\u003cli\u003eKim, S. K., Lee, J. B., Lee, H. T., Han, D. \u0026amp; Yoon, J. W. Development of antisense peptide-peptide nucleic acids against fluoroquinolone-resistant \u003cem\u003eEscherichia coli\u003c/em\u003e. \u003cem\u003eJ. Antimicrob. Chemother.\u003c/em\u003e \u003cstrong\u003e78\u003c/strong\u003e, 2052-2060 (2023). https://doi.org/10.1093/jac/dkad203\u003c/li\u003e\n\u003cli\u003eVioque, A., Arnez, J. \u0026amp; Altman, S. Protein-RNA interactions in the RNase P holoenzyme from \u003cem\u003eEscherichia coli\u003c/em\u003e. \u003cem\u003eJ. Mol. Biol.\u003c/em\u003e \u003cstrong\u003e202\u003c/strong\u003e, 835-848 (1988). https://doi.org/10.1016/0022-2836(88)90562-1\u003c/li\u003e\n\u003cli\u003eShimizu, Y.\u003cem\u003e et al.\u003c/em\u003e Cell-free translation reconstituted with purified components. \u003cem\u003eNat. Biotechnol.\u003c/em\u003e \u003cstrong\u003e19\u003c/strong\u003e, 751-755 (2001). https://doi.org/10.1038/90802\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"antisense, bridge nucleic acid, RNase P, RNase H, aminoglycoside, antibiotic resistance","lastPublishedDoi":"10.21203/rs.3.rs-7390173/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7390173/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAntisense interference with gene expression is usually achieved using nuclease-resistant oligonucleotide analogs that act by mRNA degradation, recruiting endogenous RNase H or RNase P, or steric hindrance of translation. Bridge nucleic acids (BNAs) are promising nucleotide analogs, and their chemical structure allows the development of new variants. Building on previous research, we evaluated gapmers composed of a short oligodeoxynucleotide flanked by BNA residues in a BNA\u003csub\u003e5\u003c/sub\u003e-DNA\u003csub\u003e8\u003c/sub\u003e-BNA\u003csub\u003e4\u003c/sub\u003e configuration, using available BNA variants: the original locked nucleic acid (LNA; 2\u0026prime;-O-4\u0026prime;-methylene locked nucleic acid), cET (2\u0026prime;-O,4\u0026prime;-ethyl bridge), cMOE (2\u0026prime;-O,4\u0026prime;-methoxyethyl bridge), and BNA\u003csup\u003eNC\u003c/sup\u003e (2\u0026prime;-O,4\u0026prime;-aminomethylene bridge). These gapmers were tested in vitro for their ability to direct cleavage of the \u003cem\u003eaac(6')-Ib\u003c/em\u003e mRNA, which would restore susceptibility to clinically important aminoglycosides. The assays were carried out using gapmers that target a region of the mRNA previously identified as suitable for interaction with antisense oligomers. While all gapmers showed variable RNase H-mediated activity, only the LNA-containing gapmer (LDAA) elicited RNase P-dependent degradation, demonstrating ability to mimic both RNA and DNA. Coupled in vitro transcription\u0026ndash;translation reactions using a cell lysate or a reconstituted system confirmed inhibition of expression and ruled out steric hindrance as mechanism of action. Gapmers with the LDAA structure can act as external guide sequences (EGSs), molecules that elicit RNAse P cleavage, and as antisense compounds that work via RNase H degradation. In contrast, gapmers targeting the ribosome binding site failed to recruit endogenous RNases but strongly inhibited expression by steric hindrance. Taken together, the results show that LNA-containing gapmers with the tested configuration can act through multiple mechanisms. A single molecule can elicit both RNase H- and RNase P-mediated degradation, and, when directed to other regions such as the ribosome binding site, inhibit expression through steric hindrance, supporting the potential for synergistic inhibition of gene expression when used in combination.\u003c/p\u003e","manuscriptTitle":"Bridge nucleic acid/DNA gapmers as inhibitors of gene expression by multiple antisense mechanisms","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-03 12:07:03","doi":"10.21203/rs.3.rs-7390173/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"add8bfb1-a84e-4f94-8a93-c955c23fe13b","owner":[],"postedDate":"September 3rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":53963916,"name":"Biological sciences/Biochemistry"},{"id":53963917,"name":"Biological sciences/Drug discovery"},{"id":53963918,"name":"Biological sciences/Molecular biology"}],"tags":[],"updatedAt":"2025-09-15T12:08:21+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-03 12:07:03","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7390173","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7390173","identity":"rs-7390173","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}